A Phase 1 interventional study of Combined preparation of imidazolylethylamide of pentanedioic acid and N,N'-bis-[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl] diamide of malonic acid, 90 mg + 5 mg and Combined preparation of imidazolylethylamide of pentanedioic acid and N,N'-bis-[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl] diamide of malonic acid, 90 mg + 10 mg in Influenza and Viral Respiratory Infection, sponsored by Valenta Pharm JSC. Recruiting at 1 site in Russia. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-08.
Sponsored by Valenta Pharm JSC · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Influenza, Human by Valenta Pharm JSC — 4 open to participants now, 4 under way, none of them phase 3. Influenza, Human · Valenta Pharm JSC.
Among the 15 studies in Influenza, Human by Valenta Pharm JSC, this one is the 13th largest by planned enrollment, is one of 3 that started in 2025, is one of 2 in phase 1, and was the 13th registered.
2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.
Browse Influenza, Human studies →4 of the 15 studies in Influenza, Human by Valenta Pharm JSC are open now, in 2 countries. Recruiting first, the newest first:
Valenta Pharm JSC · Sites in Russia
Ages 18–65
Valenta Pharm JSC · Sites in Russia
Ages 18–45 · Healthy volunteers
Valenta Pharm JSC · Sites in Russian Federation
Ages 13–17
By country, each count listing its studies:
Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 3 started in 2025.
This study's planned enrollment of 36 is below the median of 228 across 1,959 interventional studies indexed under Influenza, Human.
Median enrollment 240 across the 15 interventional studies. Of the 11 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Valenta Pharm JSC is the lead sponsor of 40 studies on the registry; 18 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Influenza, Human by Valenta Pharm JSC, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Single Center, First-in-human Study of Safety, Tolerability, and Pharmacokinetic Profile of Ascending Single and Multiple Doses of Ingavirin Forte, Capsules in Healthy Volunteers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Non-inclusion criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ingavirin Forte, 1 capsule (90 mg + 5 mg) taken once under fasted conditions, followed by Ingavirin Forte, 1 capsule (90 mg + 5 mg) taken twice a day for 2 days (the first dose under fasted conditions, the second dose under fed conditions - 2 hours after a meal), and once in the morning under fasted conditions on the 3rd day. Wash-out period after a single-dose period will last from 7 to 21 days.
Drug: Combined preparation of imidazolylethylamide of pentanedioic acid and N,N'-bis-[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl] diamide of malonic acid, 90 mg + 5 mg
Ingavirin Forte, 1 capsule (90 mg + 10 mg) taken once under fasted conditions, followed by Ingavirin Forte, 1 capsule (90 mg + 10 mg) taken twice a day for 2 days (the first dose on an under fasted conditions, the second dose under fed conditions - 2 hours after a meal), and once in the morning under fasted conditions on the 3rd day. Wash-out period after a single-dose period will last from 7 to 21 days.
Drug: Combined preparation of imidazolylethylamide of pentanedioic acid and N,N'-bis-[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl] diamide of malonic acid, 90 mg + 10 mg
Ingavirin Forte, 1 capsule (90 mg + 20 mg) taken once under fasted conditions, followed by Ingavirin Forte, 1 capsule (90 mg + 20 mg) taken twice a day for 2 days (the first dose under fasted conditions, the second dose under fed conditions - 2 hours after a meal), and once in the morning under fasted conditions on the 3rd day. Wash-out period after a single-dose period will last from 7 to 21 days.
Drug: Combined preparation of imidazolylethylamide of pentanedioic acid and N,N'-bis-[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl] diamide of malonic acid, 90 mg + 20 mg
Capsules, containing 90 mg of imidazolylethylamide of pentanedioic acid and 5 mg of N,N'-bis-\[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl\] diamide of malonic acid
Capsules, containing 90 mg of imidazolylethylamide of pentanedioic acid and 10 mg of N,N'-bis-\[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl\] diamide of malonic acid
Capsules, containing 90 mg of imidazolylethylamide of pentanedioic acid and 20 mg of N,N'-bis-\[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl\] diamide of malonic acid
Pharmacokinetics - Cmax
Maximum plasma concentration (Cmax) of imidazolylethylamide of pentanedioic acid and N,N'-bis-\[2-(1,3-diazocyclopent-2,4-dien-4-yl)ethyl\] diamide of malonic acid. The same analytes would be used for other pharmacokinetic measures listed below.
Time frame: From 0 to 24 hours (single dose); from 48 to 72 hours (multiple dose)
Pharmacokinetics - tmax
Time to reach Cmax (tmax)
Time frame: From 0 to 24 hours (single dose); from 48 to 72 hours (multiple dose)
Pharmacokinetics - AUC0-t
Area under the plasma concentration-time curve from time 0 to t (AUC0-t)
Time frame: From 0 to 24 hours (single dose); from 48 to 72 hours (multiple dose)
Pharmacokinetics - AUC0-inf
Area under the plasma concentration-time curve from time 0 to infinity (AUC0-inf)
Time frame: From 0 hours extrapolated to infinity after single dose and from 48 hours extrapolated to infinity after multiple dose
Pharmacokinetics - AUCextr
Extrapolated AUC defined as (AUC0-inf - AUC0-t)/AUC0-inf
Time frame: From 0 hours extrapolated to infinity after single dose and from 48 hours extrapolated to infinity after multiple dose
Pharmacokinetics - t1/2
Elimination half-life (t1/2)
Time frame: From 0 to 24 hours (single dose); from 48 to 72 hours (multiple dose)
Pharmacokinetics - kel
Elimination constant (kel)
Time frame: From 0 to 24 hours (single dose); from 48 to 72 hours (multiple dose)
Pharmacokinetics - MRT
Mean residence time (MRT)
Time frame: From 0 to 24 hours (single dose); from 48 to 72 hours (multiple dose)
Pharmacokinetics - Vd
Volume of distribution
Time frame: From 0 to 24 hours (single dose); from 48 to 72 hours (multiple dose)
Pharmacokinetics - CL
Clearance (CL)
Time frame: From 0 to 24 hours (single dose); from 48 to 72 hours (multiple dose)
Pharmacokinetics - number of terminal timepoints
Number of points in the terminal logarithmic phase used to estimate the terminal elimination rate constant
Time frame: From 0 to 24 hours (single dose); from 48 to 72 hours (multiple dose)
Pharmacokinetics - AUC0-tau
Steady state area under the plasma concentration-time curve from time 0 to t (AUC0-tau)
Time frame: From 0 to 48 hours (multiple dose)
Pharmacokinetics - Cmax,ss
Steady state maximum plasma concentration (Cmax,ss)
Time frame: From 0 to 48 hours (multiple dose)
Pharmacokinetics - tmax,ss
Steady state time to reach Cmax,ss (tmax,ss)
Time frame: From 0 to 48 hours (multiple dose)
Pharmacokinetics, urine - Aeinterval
The amount of active substance excreted in urine during each time interval (Aeinterval), calculated as the concentration in urine multiplied by the volume of urine.
Time frame: From 48 to 72 hours (multiple dose)
Pharmacokinetics, urine - Ae(0-t)
Total urinary excretion from zero to time t (Ae(0-t)), calculated as the sum of the amounts excreted during each time interval
Time frame: From 48 to 72 hours (multiple dose)
Pharmacokinetics, urine - Rmax
Maximum rate of urinary excretion (Rmax), calculated by dividing the amount of active substance excreted during each time interval by the time over which it was collected
Time frame: From 48 to 72 hours (multiple dose)
Pharmacokinetics, urine - TRmax
Time of maximum urinary excretion (TRmax), calculated as the average time interval during which Rmax was observed
Time frame: From 48 to 72 hours (multiple dose)
Pharmacokinetics, urine - Fe0-t
Fraction (% of dose) excreted from the body unchanged (Fe0-t), calculated as Ae/orally administered dose
Time frame: From 48 to 72 hours (multiple dose)
Pharmacokinetics, urine - CLR
Renal clearance (CLR), calculated as the ratio of Ae(0-t) to AUC(0-t)
Time frame: From 48 to 72 hours (multiple dose)
Adverse event type
Adverse events will be assessed by complaints, results of physical examination, results of heart rate and blood pressure assessment, results of respiratory rate assessment, body temperature, laboratory monitoring (clinical blood count, biochemical blood count, urinalysis), electrocardiography; adverse events will be classified in accordance to MedDRA.
Time frame: From Day -14 to Day -1 (screening), from Day 1 to Day 21 (single dosing and subsequent wash-out period), from Day 1 to Day 11 (multiple dosing and subsequent observation period)
Adverse event number
Number of adverse events registered during the study
Time frame: From Day -14 to Day -1 (screening), from Day 1 to Day 21 (single dosing and subsequent wash-out period), from Day 1 to Day 11 (multiple dosing and subsequent observation period)
Adverse event severety
Severity of adverse events registered during the study
Time frame: From Day -14 to Day -1 (screening), from Day 1 to Day 21 (single dosing and subsequent wash-out period), from Day 1 to Day 11 (multiple dosing and subsequent observation period)
Drop-outs associated with adverse events
The number of cases of early termination of participation in the study due to the development of adverse events and/or serious adverse events associated with the study drug
Time frame: From Day -14 to Day -1 (screening), from Day 1 to Day 21 (single dosing and subsequent wash-out period), from Day 1 to Day 11 (multiple dosing and subsequent observation period)
Safety and Tolerability: volunteer complaints
Description of any health-related complaints received from volunteer
Time frame: From Day -14 to Day -1 (screening), from Day 1 to Day 21 (single dosing and subsequent wash-out period), from Day 1 to Day 11 (multiple dosing and subsequent observation period)
Safety and Tolerability: physical examination results - cardiovascular system
An assessment of the condition of the cardiovascular system and associated symptoms on physical examination (normal condition or a description of abnormal conditions/cardiovascular symptoms, if any)
Time frame: Screening, Day 1 and 2 (single dosing), Day 1 to 4, 11 (multiple dosing)
Safety and Tolerability: physical examination results - respiratory system
An assessment of the condition of the respiratory system and associated symptoms on physical examination (normal condition or a description of abnormal conditions/respiratory symptoms, if any)
Time frame: Screening, Day 1 and 2 (single dosing), Day 1 to 4, 11 (multiple dosing)
Safety and Tolerability: physical examination results - digestive tract
An assessment of the condition of the digestive tract and associated symptoms on physical examination (normal condition or a description of abnormal conditions/digestive tract symptoms, if any)
Time frame: Screening, Day 1 and 2 (single dosing), Day 1 to 4, 11 (multiple dosing)
Safety and Tolerability: physical examination results - endocrine system
An assessment of the condition of the endocrine system and associated symptoms on physical examination (normal condition or a description of abnormal conditions/endocrine symptoms, if any)
Time frame: Screening, Day 1 and 2 (single dosing), Day 1 to 4, 11 (multiple dosing)
Safety and Tolerability: physical examination results - musculoskeletal system
An assessment of the condition of the musculoskeletal system and associated symptoms on physical examination (normal condition or a description of abnormal conditions/musculoskeletal symptoms, if any)
Time frame: Screening, Day 1 and 2 (single dosing), Day 1 to 4, 11 (multiple dosing)
Safety and Tolerability: physical examination results - nervous system
An assessment of the condition of the nervous system and associated symptoms on physical examination (normal condition or a description of abnormal conditions/neurological symptoms, if any)
Time frame: Screening, Day 1 and 2 (single dosing), Day 1 to 4, 11 (multiple dosing)
Safety and Tolerability: physical examination results - sensory systems
An assessment of the condition of the sensory systems and associated symptoms on physical examination (normal condition or a description of abnormal conditions/symptoms, if any
Time frame: Screening, Day 1 and 2 (single dosing), Day 1 to 4, 11 (multiple dosing)
Safety and Tolerability: physical examination results - skin/visible mucous membranes
An assessment of the condition of the skin/visible mucous membranes and associated symptoms on physical examination (normal condition or a description of abnormal conditions/symptoms, if any)
Time frame: Screening, Day 1 and 2 (single dosing), Day 1 to 4, 11 (multiple dosing)
Safety and Tolerability: vital signs - systolic blood pressure
Systolic blood pressure (SBP, mmHg)
Time frame: Screening, Day 1 to 2 (single dosing), Day 1 to 4, 11 (multiple dosing)
Safety and Tolerability: vital signs - diastolic blood pressure
Diastolic blood pressure (DBP, mmHg)
Time frame: Screening, Day 1 to 2 (single dosing), Day 1 to 4, 11 (multiple dosing)
Safety and Tolerability: vital signs - heart rate
Heart rate (HR, bpm)
Time frame: Screening, Day 1 to 2 (single dosing), Day 1 to 4, 11 (multiple dosing)
Safety and Tolerability: vital signs - body temperature (Celsius temperature scale)
Body temperature (Celsius temperature scale)
Time frame: Screening, Day 1 to 2 (single dosing), Day 1 to 4, 11 (multiple dosing)
Safety and Tolerability: 12-lead electrocardiogram (ECG) - heart rate
12-lead ECG (I, II, III, aVR-enhanced unipolar abduction from the right arm , aVL-enhanced unipolar abduction from the left arm, aVF - enhanced unipolar abduction from the left leg, V1-V6) taken while lying down: heart rate (beats per minute)
Time frame: Screening, Day 1 to 2 (single dosing), Day 1 to 4, 11 (multiple dosing)
Safety and Tolerability: 12-lead electrocardiogram (ECG) - PQ interval
12-lead ECG (I, II, III, aVR-enhanced unipolar abduction from the right arm , aVL-enhanced unipolar abduction from the left arm, aVF - enhanced unipolar abduction from the left leg, V1-V6) taken while lying down: PQ interval (is the period, measured in milliseconds, that extends from the beginning of the P wave (the onset of atrial depolarization) until the beginning of the QRS complex)
Time frame: Screening, Day 1 to 2 (single dosing), Day 1 to 4, 11 (multiple dosing)
Safety and Tolerability: 12-lead electrocardiogram (ECG) - QRS complex
12-lead ECG (I, II, III, aVR-enhanced unipolar abduction from the right arm , aVL-enhanced unipolar abduction from the left arm, aVF - enhanced unipolar abduction from the left leg, V1-V6) taken while lying down: QRS complex (the QRS complex is the combination of three of the graphical deflections seen on a typical electrocardiogram)
Time frame: Screening, Day 1 to 2 (single dosing), Day 1 to 4, 11 (multiple dosing)
Safety and Tolerability: 12-lead electrocardiogram (ECG) - corrected QT interval
12-lead ECG (I, II, III, aVR-enhanced unipolar abduction from the right arm , aVL-enhanced unipolar abduction from the left arm, aVF - enhanced unipolar abduction from the left leg, V1-V6) taken while lying down: corrected QT interval (distance from the beginning of the QRS complex to the end of the T wave; Fredericia correction)
Time frame: Screening, Day 1 to 2 (single dosing), Day 1 to 4, 11 (multiple dosing)
Safety and Tolerability: clinical blood test - hemoglobin
Hemoglobin (g/L)
Time frame: Screening, Day 1 and 2 (single dosing), Day 1, 3, 4, 11 (multiple dosing)
Safety and Tolerability: clinical blood test - hematocrit
Hematocrit (%)
Time frame: Screening, Day 1 and 2 (single dosing), Day 1, 3, 4, 11 (multiple dosing)
Safety and Tolerability: clinical blood test - red blood cell count
Red blood cell count (cells/L)
Time frame: Screening, Day 1 and 2 (single dosing), Day 1, 3, 4, 11 (multiple dosing)
Safety and Tolerability: clinical blood test - platelet count
Platelet count (cells/L)
Time frame: Screening, Day 1 and 2 (single dosing), Day 1, 3, 4, 11 (multiple dosing)
Safety and Tolerability: clinical blood test - leukocyte count
Leukocyte count (cells/L)
Time frame: Screening, Day 1 and 2 (single dosing), Day 1, 3, 4, 11 (multiple dosing)
Safety and Tolerability: clinical blood test - erythrocyte sedimentation rate
Erythrocyte sedimentation rate (mm/h)
Time frame: Screening, Day 1 and 2 (single dosing), Day 1, 3, 4, 11 (multiple dosing)
Safety and Tolerability: clinical blood test - myelocytes
Leukocyte formula (myelocytes, %)
Time frame: Screening, Day 1 and 2 (single dosing), Day 1, 3, 4, 11 (multiple dosing)
Safety and Tolerability: clinical blood test - band neutrophils
Leukocyte formula (band neutrophils, %)
Time frame: Screening, Day 1 and 2 (single dosing), Day 1, 3, 4, 11 (multiple dosing)
Safety and Tolerability: clinical blood test - segmented neutrophils
Leukocyte formula (segmented neutrophils, %)
Time frame: Screening, Day 1 and 2 (single dosing), Day 1, 3, 4, 11 (multiple dosing)
Safety and Tolerability: clinical blood test - eosinophils
Leukocyte formula (eosinophils, %)
Time frame: Screening, Day 1 and 2 (single dosing), Day 1, 3, 4, 11 (multiple dosing)
Safety and Tolerability: clinical blood test - basophils
Leukocyte formula (basophils, %)
Time frame: Screening, Day 1 and 2 (single dosing), Day 1, 3, 4, 11 (multiple dosing)
Safety and Tolerability: clinical blood test - monocytes
Leukocyte formula (monocytes, %)
Time frame: Screening, Day 1 and 2 (single dosing), Day 1, 3, 4, 11 (multiple dosing)
Safety and Tolerability: clinical blood test - lymphocytes
Leukocyte formula (lymphocytes, %)
Time frame: Screening, Day 1 and 2 (single dosing), Day 1, 3, 4, 11 (multiple dosing)
Safety and Tolerability: urinalysis - specific gravity
Specific gravity of the urine
Time frame: Screening, Day 2 (single dosing), Day 4, 11 (multiple dosing)
Safety and Tolerability: urinalysis - color
Color of the urine
Time frame: Screening, Day 2 (single dosing), Day 4, 11 (multiple dosing)
Safety and Tolerability: urinalysis - transparency
Transparency of the urine
Time frame: Screening, Day 2 (single dosing), Day 4, 11 (multiple dosing)
Safety and Tolerability: urinalysis - pH
pH of the urine
Time frame: Screening, Day 2 (single dosing), Day 4, 11 (multiple dosing)
Safety and Tolerability: urinalysis - protein
Protein concentration (g/L)
Time frame: Screening, Day 2 (single dosing), Day 4, 11 (multiple dosing)
Safety and Tolerability: urinalysis - glucose
Glucose concentration (mmol/L)
Time frame: Screening, Day 2 (single dosing), Day 4, 11 (multiple dosing)
Safety and Tolerability: urinalysis - red blood cells
Red blood cell content (number in sight)
Time frame: Screening, Day 2 (single dosing), Day 4, 11 (multiple dosing)
Safety and Tolerability: urinalysis - white blood cells
White blood cell content (number in sight)
Time frame: Screening, Day 2 (single dosing), Day 4, 11 (multiple dosing)
Safety and Tolerability: urinalysis - epithelial cells
Epithelial cell content (number in sight)
Time frame: Screening, Day 2 (single dosing), Day 4, 11 (multiple dosing)
Safety and Tolerability: urinalysis - casts
Presence of casts (Yes/No)
Time frame: Screening, Day 2 (single dosing), Day 4, 11 (multiple dosing)
Safety and Tolerability: urinalysis - mucus
Presence of mucus (Yes/No)
Time frame: Screening, Day 2 (single dosing), Day 4, 11 (multiple dosing)
Safety and Tolerability: urinalysis - bacteria
Presence of bacteria (Yes/No)
Time frame: Screening, Day 2 (single dosing), Day 4, 11 (multiple dosing)
Safety and Tolerability: urinalysis (microscopy)
Microscopy of urine sediment is performed if it is present
Time frame: Screening, Day 2 (single dosing), Day 4, 11 (multiple dosing)
Safety and Tolerability: blood chemistry - glucose
Glucose concentration (mmol/L)
Time frame: Screening, Day 1 and 2 (single dosing), Day 1 to 4, 11 (multiple dosing)
Safety and Tolerability: blood chemistry - cholesterol
Total cholesterol concentration (mmol/L)
Time frame: Screening, Day 1 and 2 (single dosing), Day 1 to 4, 11 (multiple dosing)
Safety and Tolerability: blood chemistry - protein
Total protein concentration (g/L)
Time frame: Screening, Day 1 and 2 (single dosing), Day 1 to 4, 11 (multiple dosing)
Safety and Tolerability: blood chemistry - bilirubin
Total bilirubin concentration (micromol/L)
Time frame: Screening, Day 1 and 2 (single dosing), Day 1 to 4, 11 (multiple dosing)
Safety and Tolerability: blood chemistry - creatinine
Creatinine concentration (micromol/L)
Time frame: Screening, Day 1 and 2 (single dosing), Day 1 to 4, 11 (multiple dosing)
Safety and Tolerability: blood chemistry - alkaline phosphatase
Alkaline phosphatase activity (U/L)
Time frame: Screening, Day 1 and 2 (single dosing), Day 1 to 4, 11 (multiple dosing)
Safety and Tolerability: blood chemistry - alanine transaminase
Alanine transaminase activity (U/L)
Time frame: Screening, Day 1 and 2 (single dosing), Day 1 to 4, 11 (multiple dosing)
Safety and Tolerability: blood chemistry - aspartate transaminase
Aspartate transaminase activity (U/L)
Time frame: Screening, Day 1 and 2 (single dosing), Day 1 to 4, 11 (multiple dosing)
Safety and Tolerability: blood chemistry - potassium concentration
Potassium (mmol/L)
Time frame: Screening, Day 1 and 2 (single dosing), Day 1 to 4, 11 (multiple dosing)
Safety and Tolerability: blood chemistry - sodium concentration
Sodium concentration (mmol/L)
Time frame: Screening, Day 1 and 2 (single dosing), Day 1 to 4, 11 (multiple dosing)
Safety and Tolerability: blood chemistry - chloride concentration
Chloride concentration (mmol/L)
Time frame: Screening, Day 1 and 2 (single dosing), Day 1 to 4, 11 (multiple dosing)
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2025 (actual). Primary completion is estimated for Dec 2025, 11 months after the start.
Of 94 industry-sponsored phase 1 interventional studies under Influenza, Human, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's planned 11 months is above that.
Counting every sponsor, half of 148 studies reached it within 11 months; a quarter within 4 and three quarters within 21.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.